Published in Journal of Experimental Medicine · View the paper (DOI)
Researchers developed a new immunotherapy approach that successfully treated glioblastoma, a fatal brain tumor, by stimulating the immune system and inducing tumor rejection. The treatment, combining intra-tumoral Interleukin-12 with CTLA-4 blockade, achieved a success rate of up to 80% in preclinical trials.
Coverage from 2 institutions